electroCore, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Thomas J. Errico
- Full Time Employees
- 83
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 200 Forge Way Rockaway NJ United States of America 07866
- IPO Date
- Jun 22, 2018
- CIK
- 0001560258
- Website
- electrocore.com
- Similar Companies
- Business
- electroCore, Inc. electroCore, Inc. (Nasdaq: ECOR) is a commercial-stage bioelectronic medicine and general wellness company that develops and commercializes non-invasive vagus nerve stimulation (nVNS) technology platforms for treating pain, neurological conditions, and wellness needs; its core products include gammaCore Sapphire, a prescription handheld device cleared by the FDA for the acute treatment of pain associated with episodic cluster headache and migraine in adult patients, adjunctive preventive treatment of cluster headache, prevention of migraine, and treatment of hemicrania continua and paroxysmal hemicrania; gammaCore for adolescent patients; Truvaga 350 and Truvaga Plus, app-enabled direct-to-consumer general wellness devices for stress reduction and mental clarity without requiring a prescription; Quell Fibromyalgia, a wearable neuromodulation platform acquired through the 2025 merger with NeuroMetrix, Inc., indicated for fibromyalgia symptoms and lower-extremity chronic pain; and TAC-STIM, a portable vagus nerve stimulator designed for military use to enhance performance and resilience. The company operates primarily in the United States, United Kingdom, and internationally, targeting patients with primary headaches, chronic pain sufferers, wellness consumers, and military personnel through prescription channels, direct-to-consumer sales, and partnerships including a Federal Supply Schedule contract with the U.S. Veterans Affairs (VA) FSS Service effective June 2025 to June 2030, supporting sales to 170 VA facilities. Founded in 2005 and headquartered in Rockaway, New Jersey, electroCore recently completed the acquisition of NeuroMetrix in May 2025, expanding its non-pharmaceutical pain management portfolio and distribution within the VA Hospital System; launched the Truvaga wellness product line; reported record 2024 net sales of $25.2 million, up 57% year-over-year driven by 85% growth in VA/DoD channel sales; secured a new independent auditor, CBIZ CPAs, following Marcum LLP's resignation amid the acquisition; and continues to pursue strategic partnerships and clinical advancements in nVNS therapy.
Company News
electroCore's Truvaga® Named Best Luxury Biohacking & Longevity Brand in the USA by Luxury Lifestyle Awards
electroCore, Inc. (ECOR) Q2 2026 Earnings Call Transcript
electroCore Q2 Earnings Call Highlights
electroCore, Inc. (ECOR) Reports Q2 Loss, Tops Revenue Estimates
electroCore Announces Second Quarter 2026 Financial Results
electroCore to Participate in Upcoming Investor Conferences
electroCore to Announce Second Quarter June 30, 2026, Financial Results on Thursday, August 6, 2026
Ecora Royalties reports 61% jump in strong quarter
New Review Examines Anatomical and Methodological Differences Between Auricular and Cervical Vagus Nerve Stimulation
electroCore, Inc. (ECOR) Presents at IAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 Transcript
electroCore to Participate in iAccess Alpha Virtual Best Ideas Summer Investment Conference
RBC reiterates 'outperform' on Ecora Royalties after Voisey's Bay site visit boosts confidence
Frontiers in Neuroscience Accepts Review Article Synthesizing Evidence that Cervical nVNS Activates the Vagus Nerve Without Surgery
electroCore to Present at the Planet MicroCap Las Vegas 2026 Powered by MicroCapClub
electroCore to Present at the Planet MicroCap Las Vegas 2026 Powered by MicroCapClub
electroCore Touts 30% Growth Outlook, VA Opportunity at LD Micro Conference
electroCore Announces Publication in JAMA Highlighting the Benefits of Adding Quell Electrical Nerve Stimulation to Outpatient Physical Therapy in Fibromyalgia
electroCore to Present at the LD Micro Invitational XVI Conference on May 18, 2026
electroCore, Inc. (ECOR) Q1 2026 Earnings Call Transcript
electroCore, Inc. (ECOR) Reports Q1 Loss, Beats Revenue Estimates